Zobrazeno 1 - 10
of 79
pro vyhledávání: '"Wendy B. London"'
Autor:
Mary Eapen, Ruta Brazauskas, David A. Williams, Mark C. Walters, Andrew St Martin, Benjamin L. Jacobs, Joseph H. Antin, Kira Bona, Sonali Chaudhury, Victoria H. Coleman-Cowger, Nancy L. DiFronzo, Erica B. Esrick, Joshua J. Field, Courtney D. Fitzhugh, Julie Kanter, Neena Kapoor, Donald B. Kohn, Lakshmanan Krishnamurti, Wendy B. London, Michael A. Pulsipher, Sohel Talib, Alexis A. Thompson, Edmund K. Waller, Ted Wun, Mary M. Horowitz
Publikováno v:
Journal of Clinical Oncology. 41:2227-2237
PURPOSE To report the incidence and risk factors for secondary neoplasm after transplantation for sickle cell disease. METHODS Included are 1,096 transplants for sickle cell disease between 1991 and 2016. There were 22 secondary neoplasms. Types incl
Autor:
Natalie S. Bezler, Maya Ilowite, Wendy B. London, Kao Pei-Chi, Steven Joffe, Jennifer W. Mack
Publikováno v:
JCO Oncology Practice. 18:e857-e868
PURPOSE: To test associations between health literacy and clinical outcomes in patients undergoing hematopoietic stem-cell transplantation (HSCT). METHODS: English- and Spanish-speaking patients age ≥ 18 years were recruited while admitted for firs
Autor:
Hannah G. Bender, Meredith S. Irwin, Michael D. Hogarty, Robert Castleberry, John M. Maris, Pei-Chi Kao, Fan F. Zhang, Arlene Naranjo, Susan L. Cohn, Wendy B. London
Publikováno v:
Journal of Clinical Oncology.
PURPOSE In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for high-risk assignment was raised from 365 days (12 months) to 547 days (18 mo
Autor:
Steven G. DuBois, Stephan A. Grupp, John J. Doski, Daphne A. Haas-Kogan, Julie R. Park, Lisa Diller, Geetika Khanna, Steve Braunstein, Susan G. Kreissman, Wendy B. London, Stephan D. Voss, Arlene Naranjo, Kevin X. Liu, Fan F Zhang, James D. Geiger
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 24
J Clin Oncol
J Clin Oncol
PURPOSE A primary objective of the Children’s Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing local dose of radiation to a residual primary tumor on the cumulative incidence of local progression (CILP) in patien
Autor:
Rajen Mody, Barry L. Shulkin, Mildred Felder, Paul M. Sondel, Howard M. Katzenstein, Wendy B. London, Shahab Asgharzadeh, Alice L. Yu, Julia Glade-Bender, Rochelle Bagatell, Marguerite T. Parisi, Arlene Naranjo, Jennifer Birstler, Fan F Zhang, Mitchell B. Diccianni, Jacquelyn A. Hank, Julie R. Park, Sabah-E-Noor Servaes, John M. Maris
Publikováno v:
J Clin Oncol
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 38, iss 19
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children’s Oncology Gr
Autor:
Wendy B. London, Samuel L. Volchenboum, Arlene Naranjo, Susan L. Cohn, Dominique Valteau-Couanet, Julie R. Park, Andrew D.J. Pearson, Meredith S. Irwin, Michael D. Hogarty, Elizabeth A. Sokol, Gudrun Schleiermacher, Mark A. Applebaum, Ami V. Desai
Publikováno v:
J Clin Oncol
PURPOSE The Children’s Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Clas
Autor:
Natia Esiashvili, Edward F. Attiyeh, Peter Mattei, Susan L. Cohn, Wendy B. London, Arlene Naranjo, Araz Marachelian, Sheena C. Tenney, Mary Lou Schmidt, John M. Maris, E. Stanton Adkins, Katherine K. Matthay, Julie M. Gastier-Foster, Howard M. Katzenstein, Margaret H. Collins, Clare J. Twist, Julie R. Park, Michael H. Handler, Hiroyuki Shimada, Elizabeth Wagner, Michael D. Hogarty
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 34
J Clin Oncol
J Clin Oncol
PURPOSE The primary objective of the Children’s Oncology Group study ANBL0531 (ClinicalTrials.gov identifier: NCT00499616 ) was to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algor
Autor:
Wendy B. London, Hannah Bender, Meredith Irwin, Michael D. Hogarty, Robert P. Castleberry, John M. Maris, Pei-Chi Kao, Arlene Naranjo, Susan Lerner Cohn
Publikováno v:
Journal of Clinical Oncology. 40:10013-10013
10013 Background: In 2006, COG reclassified subgroups of toddlers diagnosed with neuroblastoma from high-(HR) to intermediate-risk (IR), when the age cut-off for increased risk was raised from 365 days (12 mo) to 547 days (18 mo) (London, J Clin Onc
Autor:
Kevin M. Campbell, Pei-Chi Kao, Arlene Naranjo, Takehiko Kamijo, Ramya Ramanujachar, Wendy B. London, Steven G. DuBois
Publikováno v:
Journal of Clinical Oncology. 40:10044-10044
10044 Background: Neuroblastoma (NB) presenting with INRGSS MS metastatic pattern highlights the extreme heterogeneity within NB and subsequent difficulty in risk assignment. Depending on tumor biology, patients with stage MS disease may be classifie
Autor:
David Stephen Shulman, Priscilla Merriam, Edwin Choy, Lillian M. Guenther, Kerri Cavanaugh, Pei-Chi Kao, Andrew Posner, Grace Fairchild, Emma Barker, Kimberly Stegmaier, Brian D. Crompton, Wendy B. London, Steven G. DuBois
Publikováno v:
Journal of Clinical Oncology. 40:e23507-e23507
e23507 Background: Ewing sarcoma (EwS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. CDK4 is a known genomic vulnerability in EwS, but an unappealing monotherapy target given propensity for innate resistance.